

Adeboye O Osunkoya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/341091/publications.pdf>

Version: 2024-02-01

111
papers

3,587
citations

182225

30
h-index

175968

55
g-index

113
all docs

113
docs citations

113
times ranked

5501
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicopathologic analysis of patients undergoing repeat transurethral resection of bladder tumour following an initial diagnosis of urothelial carcinoma with lamina propria invasion and variant/divergent histology. <i>Journal of Clinical Pathology</i> , 2023, 76, 256-260.	1.0	0
2	A Contemporary Clinicopathologic Analysis of Primary Urothelial Carcinoma of the Urethra Without Concurrent Renal Pelvic, Ureteral, or Bladder Carcinoma. <i>International Journal of Surgical Pathology</i> , 2022, 30, 15-22.	0.4	4
3	Secondary malignancy after urologic reconstruction procedures: a multi-institutional case series. <i>Human Pathology</i> , 2022, 119, 69-78.	1.1	6
4	Recurrent KRAS mutations are early events in the development of papillary renal neoplasm with reverse polarity. <i>Modern Pathology</i> , 2022, 35, 1279-1286.	2.9	17
5	The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 715-727.	1.1	0
6	Alterations in homologous recombination repair genes in prostate cancer brain metastases. <i>Nature Communications</i> , 2022, 13, 2400.	5.8	13
7	Histopathologic findings in patients who have undergone blue light cystoscopy and bladder biopsy or transurethral resection: A contemporary clinicopathologic analysis of 100 cases. <i>Pathology Research and Practice</i> , 2022, 234, 153916.	1.0	1
8	Prostate cancer histopathology using label-free multispectral deep-UV microscopy quantifies phenotypes of tumor aggressiveness and enables multiple diagnostic virtual stains. <i>Scientific Reports</i> , 2022, 12, .	1.6	17
9	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 461-493.	1.2	143
10	Surgical Pathology Findings in Patients Who Have Undergone Radical Cystectomy/Cystoprostatectomy With Extended Versus Standard Lymph Node Dissection for Urothelial Carcinoma of the Bladder: A Contemporary Analysis. <i>International Journal of Surgical Pathology</i> , 2021, 29, 150-154.	0.4	0
11	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 295.e1-295.e8.	0.8	6
12	Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 30-34.	0.9	8
13	Invasive poorly differentiated adenocarcinoma of the bladder following augmentation cystoplasty: a multi-institutional clinicopathological study. <i>Pathology</i> , 2021, 53, 214-219.	0.3	4
14	Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. <i>Theranostics</i> , 2021, 11, 6873-6890.	4.6	21
15	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. <i>Advances in Anatomic Pathology</i> , 2021, 28, 179-195.	2.4	23
16	Skene gland adenocarcinoma: Clinicopathologic features, comprehensive biomarker analysis, and review of the literature. <i>Pathology International</i> , 2021, 71, 712-714.	0.6	5
17	Small-Cell Carcinoma of the Prostate: Report of Outcomes of Localized Disease Using the National Cancer Database. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e193-e199.	0.9	1
18	Metastatic urothelial carcinoma to the brain, spinal cord and spine: A contemporary multi-institutional clinicopathologic analysis of 24 cases. <i>Pathology Research and Practice</i> , 2021, 224, 153537.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Testicular Germ-Cell Tumors with Spermatic Cord Involvement: A Retrospective International Multi-Institutional Experience. <i>Modern Pathology</i> , 2021, , .	2.9	4
20	Primary urothelial carcinoma of the ureter without concurrent renal pelvic or bladder carcinoma: A contemporary clinicopathologic analysis. <i>Pathology Research and Practice</i> , 2021, 226, 153584.	1.0	0
21	Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey. <i>Journal of Clinical Pathology</i> , 2021, 74, 291-299.	1.0	14
22	PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates. <i>Modern Pathology</i> , 2020, 33, 1165-1171.	2.9	18
23	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. <i>American Journal of Surgical Pathology</i> , 2020, 44, 673-680.	2.1	31
24	In-Bore MRI-guided Prostate Biopsies in Patients with Prior Positive Transrectal USâ€“guided Biopsy Results: Pathologic Outcomes and Predictors of Missed Cancers. <i>Radiology Imaging Cancer</i> , 2020, 2, e190078.	0.7	6
25	The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression. <i>Translational Oncology</i> , 2020, 13, 100751.	1.7	17
26	Genital verruciform xanthoma: lessons from a contemporary multiâ€“institutional series. <i>Histopathology</i> , 2020, 77, 841-846.	1.6	2
27	Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis. <i>International Journal of Urology</i> , 2020, 27, 790-797.	0.5	7
28	[¹⁸ F]Fluciclovine Positron Emission Tomography/Computerized Tomography for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 734-740.	0.2	16
29	A Rare Case of Vena Cava Tumor Thrombus Associated With Epithelioid Angiomyolipoma. <i>Urology</i> , 2020, 142, e4-e7.	0.5	2
30	Invasive high-grade urothelial carcinoma of the bladder, renal pelvis, ureter, and prostatic urethra arising in a background of urothelial carcinoma with an inverted growth pattern: a contemporary clinicopathological analysis of 91 cases. <i>Human Pathology</i> , 2019, 92, 18-24.	1.1	5
31	MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. <i>Modern Pathology</i> , 2019, 32, 1666-1674.	2.9	13
32	¹⁸F-Fluciclovine Parameters on Targeted Prostate Biopsy Associated with True Positivity in Recurrent Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1531-1536.	2.8	13
33	In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRI. <i>Radiology Imaging Cancer</i> , 2019, 1, e190016.	0.7	1
34	An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. <i>Nature</i> , 2019, 576, 465-470.	18.7	510
35	Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 413-421.	0.2	12
36	Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1413519.	2.1	21

#	ARTICLE	IF	CITATIONS
37	In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? a pilot test-retest reliability study. <i>British Journal of Radiology</i> , 2018, 91, 20170603.	1.0	3
38	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 279-292.	2.1	101
39	Mucinous and secondary tumors of the prostate. <i>Modern Pathology</i> , 2018, 31, 80-95.	2.9	37
40	Prospective evaluation of fluciclovine (18 F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients. <i>European Journal of Radiology</i> , 2018, 102, 1-8.	1.2	32
41	Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. <i>European Urology Focus</i> , 2018, 4, 880-888.	1.6	25
42	Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. <i>Modern Pathology</i> , 2018, 31, 179-197.	2.9	73
43	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1571-1584.	2.1	34
44	Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer. <i>Cancers</i> , 2018, 10, 379.	1.7	21
45	Benign vascular tumors, cysts, and pseudocysts of the adrenal gland: a contemporary multi-institutional clinicopathological analysis of 55 cases. <i>Human Pathology</i> , 2018, 82, 95-102.	1.1	13
46	<i>TERT</i> promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract. <i>Future Oncology</i> , 2017, 13, 705-714.	1.1	22
47	Biomarker, Molecular, and Technologic Advances in Urologic Pathology, Oncology, and Imaging. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 499-516.	1.2	1
48	Solitary fibrous tumour of the genitourinary tract: a clinicopathological study of 11 cases and their association with the <i>NAB2-STAT6</i> fusion gene. <i>Journal of Clinical Pathology</i> , 2017, 70, 508-514.	1.0	20
49	Urothelial carcinoma involving the ureteral orifice: a clinicopathologic analysis of 93 cases. <i>Human Pathology</i> , 2017, 65, 101-106.	1.1	6
50	Time-dependent effects of prognostic biomarkers of systemic inflammation in patients with metastatic renal cell carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831770551.	0.8	13
51	Do Nonseminomatous Germ Cell Tumors of the Testis With Lymphovascular Invasion of the Spermatic Cord Merit Staging as pT3?. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1397-1402.	2.1	15
52	Cytologic predictors of malignancy in bile duct brushings: a multi-reviewer analysis of 60 cases. <i>Modern Pathology</i> , 2017, 30, 1273-1286.	2.9	24
53	Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. <i>Oncotarget</i> , 2017, 8, 54096-54105.	0.8	22
54	Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. <i>Cancer Discovery</i> , 2016, 6, 1258-1266.	7.7	66

#	ARTICLE	IF	CITATIONS
55	Surgical Management of Primary Scrotal Cancer. Urologic Clinics of North America, 2016, 43, 531-544.	0.8	9
56	Human epidermal growth factor receptor 2 expression in micropapillary urothelial carcinoma of the bladder: an analysis of 27 cases. Human Pathology, 2016, 57, 160-164.	1.1	12
57	Major histocompatibility complex I upregulation in clear cell renal cell carcinoma is associated with increased survival. Asian Journal of Urology, 2016, 3, 75-81.	0.5	4
58	Primary mucinous adenocarcinoma of the female urethra: a contemporary clinicopathologic analysis. Human Pathology, 2016, 47, 132-137.	1.1	20
59	SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation. Cancer Research, 2016, 76, 1112-1121.	0.4	67
60	GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas. Human Pathology, 2016, 47, 26-31.	1.1	75
61	Renal cell carcinoma with vena caval involvement: a contemporary clinicopathologic analysis of 53 cases. Human Pathology, 2016, 49, 83-89.	1.1	4
62	Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence <i>in situ</i> hybridization for the detection of anaplastic lymphoma kinase alterations. Histopathology, 2015, 67, 20-38.	1.6	19
63	Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment. Bone, 2015, 78, 81-86.	1.4	44
64	High Expression of Major Histocompatibility Complex Class I in Clear Cell Renal Cell Carcinoma Is Associated with Improved Prognosis. Urologia Internationalis, 2015, 95, 72-78.	0.6	2
65	Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR. Human Pathology, 2015, 46, 805-812.	1.1	34
66	Pendrin localizes to the adrenal medulla and modulates catecholamine release. American Journal of Physiology - Endocrinology and Metabolism, 2015, 309, E534-E545.	1.8	23
67	Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Modern Pathology, 2015, 28, 446-456.	2.9	49
68	Increased androgen receptor gene copy number is associated with <i>TMPRSS2-ERG</i> rearrangement in prostatic small cell carcinoma. Molecular Carcinogenesis, 2015, 54, 900-907.	1.3	28
69	Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases. Canadian Journal of Urology, 2015, 22, 7783-7.	0.0	12
70	ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma. Modern Pathology, 2014, 27, 1174-1178.	2.9	22
71	Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations. Modern Pathology, 2014, 27, 1540-1548.	2.9	19
72	Gene expression profiling of clear cell papillary renal cell carcinoma: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Modern Pathology, 2014, 27, 222-230.	2.9	38

#	ARTICLE	IF	CITATIONS
73	GATA3 expression in sarcomatoid urothelial carcinoma of the bladder. <i>Human Pathology</i> , 2014, 45, 1625-1629.	1.1	17
74	Idiopathic granulomatous orchitis: morphology and evaluation of its relationship to IgG4 related disease. <i>Human Pathology</i> , 2014, 45, 844-850.	1.1	11
75	Global Transcriptome Analysis of Formalin-Fixed Prostate Cancer Specimens Identifies Biomarkers of Disease Recurrence. <i>Cancer Research</i> , 2014, 74, 3228-3237.	0.4	111
76	Expression of MLH1 and MSH2 in urothelial carcinoma of the renal pelvis. <i>Tumor Biology</i> , 2014, 35, 8743-8747.	0.8	10
77	Anti-3- [¹⁸ F]FACBC Positron Emission Tomography-Computerized Tomography and [¹¹¹ In]-Capromab Pendetide Single Photon Emission Computerized Tomography-Computerized Tomography for Recurrent Prostate Carcinoma: Results of a Prospective Clinical Trial. <i>Journal of Urology</i> , 2014, 191, 1446-1453.	0.2	165
78	Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 2544-50.	0.5	9
79	Optical Imaging of Kidney Cancer with Novel Near Infrared Heptamethine Carbocyanine Fluorescent Dyes. <i>Journal of Urology</i> , 2013, 189, 702-710.	0.2	78
80	ERG expression in mucinous prostatic adenocarcinoma and prostatic adenocarcinoma with mucinous features: comparison with conventional prostatic adenocarcinoma. <i>Human Pathology</i> , 2013, 44, 2241-2246.	1.1	20
81	BCA2 is differentially expressed in renal oncocytoma: an analysis of 158 renal neoplasms. <i>Tumor Biology</i> , 2013, 34, 787-791.	0.8	11
82	Histologic findings on prostate needle core biopsies following cryotherapy as monotherapy for prostatic adenocarcinoma. <i>Human Pathology</i> , 2013, 44, 867-872.	1.1	8
83	RNAseq Analysis of FFPE Radical Prostatectomy Specimens Identifies Predictors of Biochemical Recurrence. <i>FASEB Journal</i> , 2013, 27, 471.8.	0.2	0
84	Schistosomiasis of the prostate: a case report. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , 2013, 35, 178-80.	0.2	2
85	Biological interpretation of morphological patterns in histopathological whole-slide images. , 2012, 2012, 218-225.		50
86	Update on prostate pathology. <i>Pathology</i> , 2012, 44, 391-406.	0.3	12
87	CDX-2 expression in malignant germ cell tumors of the testes, intratubular germ cell neoplasia, and normal seminiferous tubules. <i>Tumor Biology</i> , 2012, 33, 2185-2188.	0.8	14
88	Practical issues and pitfalls in staging tumors of the genitourinary tract. <i>Seminars in Diagnostic Pathology</i> , 2012, 29, 154-166.	1.0	25
89	Protein-Coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy. <i>American Journal of Pathology</i> , 2011, 179, 46-54.	1.9	92
90	Urothelial carcinoma of the bladder with transmural and direct prostatic stromal invasion: does extent of stromal invasion significantly impact patient outcome?. <i>Human Pathology</i> , 2011, 42, 51-56.	1.1	15

#	ARTICLE	IF	CITATIONS
91	Micropapillary urothelial carcinoma of the urinary bladder: A clinicopathological analysis of 24 cases. <i>International Journal of Urology</i> , 2011, 18, 49-54.	0.5	18
92	Expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma: correlation with pathological parameters in 110 patients. <i>Tumor Biology</i> , 2011, 32, 375-380.	0.8	6
93	E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma. <i>Modern Pathology</i> , 2011, 24, 241-247.	2.9	48
94	ERG and TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. <i>Modern Pathology</i> , 2011, 24, 1120-1127.	2.9	130
95	Rete testis invasion by malignant germ cell tumor and/or intratubular germ cell neoplasia: what is the significance of this finding?. <i>Human Pathology</i> , 2010, 41, 1339-1344.	1.1	24
96	Urothelial carcinoma with villoglandular differentiation: a study of 14 cases. <i>Modern Pathology</i> , 2009, 22, 1280-1286.	2.9	48
97	Evaluation of modern pathological criteria for positive margins in radical prostatectomy specimens and their use for predicting biochemical recurrence. <i>BJU International</i> , 2009, 103, 327-331.	1.3	29
98	Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma. <i>Human Pathology</i> , 2009, 40, 206-210.	1.1	66
99	Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis. <i>Human Pathology</i> , 2009, 40, 1671-1678.	1.1	24
100	Comparison of Gene Expression Profiles in Tubulocystic Carcinoma and Collecting Duct Carcinoma of the Kidney. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1103-1106.	2.1	67
101	Plasmacytoid Urothelial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 417-424.	2.1	114
102	Protein-coding and MicroRNA Biomarker Gene Panels Predictive of Clinical Recurrence in Prostate Cancer. <i>FASEB Journal</i> , 2009, 23, 361.2.	0.2	0
103	Reduced Rap1 Signaling Is Associated with Prostate Cancer Progression, Migration, Invasion, and Metastasis. <i>FASEB Journal</i> , 2009, 23, 438.2.	0.2	0
104	MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: an analysis of 50 cases on radical prostatectomy. <i>Modern Pathology</i> , 2008, 21, 789-794.	2.9	23
105	A Clinicopathologic Study of Preoperative and Postoperative Findings with Minute Gleason 3+3=6 Cancer at Radical Prostatectomy. <i>Urology</i> , 2008, 72, 638-640.	0.5	4
106	Residual Tumor Potentially Left Behind After Local Ablation Therapy in Prostate Adenocarcinoma. <i>Journal of Urology</i> , 2008, 179, 2203-2206.	0.2	61
107	The Symphony protocol for H&E staining of prostatic adenocarcinoma on needle biopsy: a multicentre analysis of 120 cases. <i>Pathology</i> , 2008, 40, 450-456.	0.3	3
108	Prognosis of Mucinous Adenocarcinoma of the Prostate Treated by Radical Prostatectomy. <i>American Journal of Surgical Pathology</i> , 2008, 32, 468-472.	2.1	91

#	ARTICLE	IF	CITATIONS
109	Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases. American Journal of Surgical Pathology, 2008, 32, 461-467.	2.1	95
110	Primary Mucin-producing Urothelial-type Adenocarcinoma of Prostate: Report of 15 Cases. American Journal of Surgical Pathology, 2007, 31, 1323-1329.	2.1	72
111	Colorectal adenocarcinoma involving the prostate: report of 9 cases. Human Pathology, 2007, 38, 1836-1841.	1.1	40